NCT02862574 - Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 15, 2016

Primary Completion Date

June 26, 2017

Study Completion Date

August 7, 2017

Conditions

Rheumatoid Arthritis

Interventions

DRUG

Andecaliximab

Administered via subcutaneous injection once weekly

DRUG

Placebo

Administered via subcutaneous injection once weekly

DRUG

Methotrexate

Administered orally weekly as part of the participant's current treatment regimen

DRUG

TNF Inhibitor

An approved stable subcutaneous formulation of one of the following TNF inhibitors may include adalimumab, certolizumab, etanercept, or golimumab.

Trial Locations (8)

Altoona Center for Clinical Research, Duncansville

Omega Research Consultants, LLC, DeBary

Accurate Clinical Research, San Antonio

Tekton Research, Austin

Albuquerque Center for Rheumatology, Albuquerque

G. Timothy Kelly, MD, Las Vegas

Stanford University, Palo Alto

Dartmouth-Hitchcock Medical Center, Lebanon